Trimebutine prevents corneal inflammation in a rat alkali burn model.
Sci Rep
; 14(1): 12111, 2024 05 27.
Article
en En
| MEDLINE
| ID: mdl-38802470
ABSTRACT
Alkaline burns to the cornea lead to loss of corneal transparency, which is essential for normal vision. We used a rat corneal alkaline burn model to investigate the effect of ophthalmic trimebutine solution on healing wounds caused by alkaline burns. Trimebutine, an inhibitor of the high-mobility group box 1-receptor for advanced glycation end products, when topically applied to the burned cornea, suppressed macrophage infiltration in the early phase and neutrophil infiltration in the late phase at the wound site. It also inhibited neovascularization and myofibroblast development in the late phase. Furthermore, trimebutine effectively inhibited interleukin-1ß expression in the injured cornea. It reduced scar formation by decreasing the expression of type III collagen. These findings suggest that trimebutine may represent a novel therapeutic strategy for corneal wounds, not only through its anti-inflammatory effects but also by preventing neovascularization.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Cicatrización de Heridas
/
Quemaduras Químicas
/
Quemaduras Oculares
/
Córnea
/
Modelos Animales de Enfermedad
/
Álcalis
Idioma:
En
Revista:
Sci Rep
/
Sci. rep. (Nat. Publ. Group)
/
Scientific reports (Nature Publishing Group)
Año:
2024
Tipo del documento:
Article
País de afiliación:
Japón